Across TCGA pan-cancer cohorts, KREMEN1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KREMEN1 data layer compared with 1 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher KREMEN1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KREMEN1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

GBM, LUAD, and HNSC are the cancer types where KREMEN1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Tertile	All	0.181	0.689	.049	3	view →
LUAD	DFS	Median	II,III,IV	0.220	0.705	.035	3	view →
HNSC	DFS	Median	All	0.942	0.715	.021	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: KREMEN1 tumor-vs-normal RNA expression · all KREMEN1 data types